Key result
Immunotherapy with rituximab led to significant clinical improvement at 6-month follow-up in a 66-year-old male with stage IV primary pulmonary MALToma.
Why the study?
Primary pulmonary MALToma is rare, and atypical symptoms and nonspecific chest CT features make diagnosis difficult and delay treatment.
Does immunotherapy with rituximab improve clinical outcomes in a patient with stage IV primary pulmonary MALToma?
Case Report (n=1)
Does immunotherapy with rituximab improve clinical outcomes in a patient with stage IV primary pulmonary MALToma?
Immunotherapy with rituximab can lead to significant clinical improvement in patients with advanced primary pulmonary MALToma.
No takes yet. Share an insight, caveat, or question.
Case report underscores diagnostic challenges in primary pulmonary MALToma; leaves open need for prospective data on optimal therapy.
Gu et al. (2023) conducted a case report in Primary pulmonary mucosa-associated lymphoid tissue lymphoma (MALToma) (n=1). Immunotherapy with anti-CD20 monoclonal antibody (rituximab) was evaluated on Clinical improvement. Immunotherapy with rituximab led to significant clinical improvement at 6-month follow-up in a 66-year-old male with stage IV primary pulmonary MALToma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: